Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs. As Healio previously reported, the FDA approved TV-46000 (Uzedy; Teva Pharmaceuticals, MedinCell), a long-acting subcutaneous risperidone injection, in April 2023 for the treatment